BioCentury | Oct 23, 2017
Preclinical News

Researchers identify new targets for DMD

...the primary and secondary endpoints in a Phase II trial to treat heart failure. The CVie Therapeutics Ltd....
BioCentury | Aug 22, 2016
Company News

Lee’s Pharmaceutical Holdings Ltd., ScinoPharm Taiwan deal

...Lee’s Pharmaceutical’s CVie Therapeutics Ltd. subsidiary and ScinoPharm partnered to discover and develop “orally available” analogs of CVie’s...
BioCentury | Apr 14, 2014
Clinical News

Kalbitor ecallantide regulatory update

...Dyax markets the subcutaneously delivered yeast-derived recombinant plasma kallikrein inhibitor in the U.S. Lee's Pharmaceutical's CVie Therapeutics...
BioCentury | Feb 18, 2013
Company News

Dyax, Lee's Pharmaceutical deal

...Dyax granted Lee's CVie Therapeutics subsidiary exclusive rights to develop and commercialize Kalbitor ecallantide to treat hereditary...
Items per page:
1 - 4 of 4
BioCentury | Oct 23, 2017
Preclinical News

Researchers identify new targets for DMD

...the primary and secondary endpoints in a Phase II trial to treat heart failure. The CVie Therapeutics Ltd....
BioCentury | Aug 22, 2016
Company News

Lee’s Pharmaceutical Holdings Ltd., ScinoPharm Taiwan deal

...Lee’s Pharmaceutical’s CVie Therapeutics Ltd. subsidiary and ScinoPharm partnered to discover and develop “orally available” analogs of CVie’s...
BioCentury | Apr 14, 2014
Clinical News

Kalbitor ecallantide regulatory update

...Dyax markets the subcutaneously delivered yeast-derived recombinant plasma kallikrein inhibitor in the U.S. Lee's Pharmaceutical's CVie Therapeutics...
BioCentury | Feb 18, 2013
Company News

Dyax, Lee's Pharmaceutical deal

...Dyax granted Lee's CVie Therapeutics subsidiary exclusive rights to develop and commercialize Kalbitor ecallantide to treat hereditary...
Items per page:
1 - 4 of 4